KERX Financial Facts
Net loss: -41.7MBasic and diluted net loss per common share: -0.39
See Full Income Statement
Total liabilities and stockholders' equity: 168.63M
Accrued compensation and related liabilities: 4.92M
See Full Balance Sheet
Keryx Biopharmaceuticals Inc. (KERX) Earnings
|
Expand Research on KERX
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -97.1% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -2.5% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2/7/18 |  |
Q417 | -$0.26 | -$0.18 | -$0.08 | $18.7M | $17.53M | = |  | | Details |
| 7/27/17 | Q217 | -$0.77 | -$0.18 | -$0.59 | $15.1M | $14.51M | = | | | Details | |
| 11/7/17 | |
Q317 | -$0.20 | -$0.18 | -$0.02 | $15M | $18.04M | = | | | Details |
| 5/4/17 | |
Q117 | -$0.21 | -$0.20 | -$0.01 | $11.8M | $10.27M | = | | | Details |
5/8/14  |
|
Q114 | -$0.15 | -$0.08 | -$0.07 | $10M | $9.91M | N/A | | | Details |
| 3/1/17 | |
Q416 | -$0.32 | -$0.25 | -$0.07 | $9.5M | $8.41M | = | | | Details |
| 8/1/16 | Q216 | -$0.42 | -$0.28 | -$0.14 | $9.3M | $8.6M | N/A | | | Details | |
| 5/7/13 | Q113 | -$0.03 | -$0.01 | -$0.02 | $7M | $5.83M | N/A | | | Details |
